In triple-negative breast cancer lung metastasis models, palmatine treatment dose-dependently improves metastatic lung lesions by downregulating metastasis-associated protein 1 (MTA1) and upregulating tumor suppressor p53 expression, while preserving lung morphology (Ativui et al., 2022). Here, MTA1 is linked to triple-negative breast carcinoma.